Telix Just Bet $2.35 Billion That Radioactive Drugs Are the Future

On the pipeline side, ITM brings ITM-11, a lutetium-177-based therapy for gastroenteropancreatic neuroendocrine tumors (GEP-NETs, a type of cancer that forms in the digestive tract). ITM-11 has already completed Phase 3 testing, making it a near-term commercial opportunity.

The Supply Chain Problem Nobody Talks About

To understand why this deal matters, you need to understand the bottleneck.

Radiopharmaceuticals aren't like pills. You can't stockpile them in a warehouse. Isotopes decay; Lu-177 has a half-life of about 6.7 days, meaning half of it is gone in a week. That makes manufacturing, logistics, and timing incredibly complex. Every batch is a race against physics.

And the supply chain is painfully concentrated. Only a handful of nuclear reactors worldwide can produce clinical-grade Lu-177 at scale. When one goes down for maintenance, global shipments get disrupted. The feedstock for Lu-177 production, enriched ytterbium-176, has historically come primarily from Russia, adding a layer of geopolitical risk that keeps supply chain managers up at night.

New reactor projects take five to ten years from construction start to commissioning, with total timelines including licensing often stretching much longer. You can't just flip a switch when demand spikes. And demand has been spiking hard, driven largely by Pluvicto's commercial success. Multiple sources confirm that Lu-177 demand outstripped supply between 2023 and 2025.

Actinium-225 faces an even tighter squeeze. Global production depends on a handful of specialized facilities, and the technical barriers to scaling are enormous.

So when Telix buys ITM, it's not just buying a pipeline. It's buying guaranteed access to the most constrained resource in oncology's hottest sector.

The Radiopharmaceutical Gold Rush

Telix isn't acting in a vacuum. The past three years have been an absolute M&A frenzy in radiopharmaceuticals.

Bristol Myers Squibb kicked things off by scooping up RayzeBio for $4.1 billion in early 2024. AstraZeneca grabbed Fusion Pharmaceuticals for up to $2.4 billion around the same time. Eli Lilly bought Point Biopharma, and Novartis added Mariana Oncology for $1 billion upfront (plus $750 million in milestones).

That was the first wave: big pharma buying its way into the space. What's happening now, in 2025 and 2026, is a second wave. Specialist radiopharmaceutical companies are merging with each other to build scale. The announced Curium-Lantheus combination and now Telix-ITM represent this shift toward platform-scale competition. It's no longer enough to have one promising drug. You need isotope supply, manufacturing capacity, distribution networks, and a deep pipeline, all under one roof.

Bull Case vs. Bear Case

The optimists see this as Telix building a moat. The combined company is projected to exceed $1.3 billion in pro forma 2026 revenue, according to management estimates. Telix gets a near-approval-ready therapeutic (ITM-11) that lets it enter a validated market quickly. It locks down isotope supply in a sector where supply is everything. And it diversifies beyond its prostate cancer imaging roots into broader oncology.

The skeptics see a company stretching. The purchase price is large relative to Telix's size. The stock-heavy payment means existing shareholders take a dilution hit. And $700 million in contingent milestones means a lot of value depends on ITM-11 actually getting approved and selling well. That's not a guarantee; it's an expensive bet.

The stock market, at least initially, leaned toward the skeptics. Telix shares fell after the announcement, despite generally supportive analyst commentary.

What This Really Means

Zoom out, and the Telix-ITM deal tells a bigger story. Radiopharmaceuticals have gone from a quirky corner of oncology to a strategic M&A battleground in roughly three years. The drugs work. The market is growing. And the companies that control the supply chain (the isotopes, the manufacturing, the logistics) will have an enormous competitive advantage.

Telix is betting $2.35 billion that owning the full stack, from isotope production to drug development to commercial distribution, is the winning formula. Whether the price was right will take years to judge. But the thesis? In a world where the raw ingredients for radioactive cancer drugs are scarcer than the drugs themselves, buying the factory makes a lot of sense.

Merck Just Paid $400M for a Drug That Doesn't Exist Yet

Merck just dropped $400 million on a Chinese biotech's preclinical cancer drug targeting a protein scientists called "undruggable" for 40 years. The KRAS G12D race is on, and Merck's gamble says everything about where Big Pharma is shopping for its next blockbuster.